Clinical Trial Update: Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack [Phase 2]

View source ↗

Summary

Phase 2 trial assessing dosing and safety of the oral FXIa inhibitor BAY 2433334 after acute myocardial infarction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• BAY 2433334 (BAY 2433334)

Snippet

Sponsor: Bayer | Conditions: Acute Myocardial Infarction | Phase 2 | Status: COMPLETED | Results posted: 2023-04-05